Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
|
|
Moscow Times (12.21.06) - Friday, December 22, 2006
Carl Schreck
The decree was issued quietly after AIDS activists and the Federal AIDS Center (FAC) worked together for months on a planned list of treatments, said Vadim Pokrovsky. "I didn't even find out about it until three weeks after it was issued," said Russia's top AIDS official. "We worked closely with them on standards approved in August. It was clear that a bureaucrat with no understanding of medical treatment for people with HIV and AIDS issued this decree."
The decree would procure Prezista (darunavir), a protease inhibitor produced in Russia by Makiz-Pharma, for about 3,000 patients next year. It was not on the original list of treatments, as AIDS experts consider it too expensive and unsuitable for Russia's AIDS patients.
Mikhail Grishankov, head of the Duma's anti-corruption committee, told the news outlet Kommersant he believes the decree was issued "in the interest of specific companies." He declined to elaborate but promises an investigation.
Makiz-Pharma spokesperson Yury Boryan said he was unaware of any forthcoming government contracts. However, he said his company would "battle in a civilized fashion, and not like cave-dwellers, for the right to sign such a contract with the government."
"The tender for procurement of antiretrovirals must not take place until a new standard is developed," the Community of People Living with HIV said in a statement.
The Health Ministry did not reply to a request for comment.
061222
AD062489
Copyright © 2006 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.